Volume | 572,161 |
|
|||||
News | - | ||||||
Day High | 1.65 | Low High |
|||||
Day Low | 1.44 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BioAtla Inc | BCAB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.65 | 1.44 | 1.65 | 1.52 | 1.65 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4,785 | 572,161 | US$ 1.53 | US$ 875,028 | - | 1.24 - 4.02 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:12:49 | 30 | US$ 1.47 | USD |
BioAtla Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
72.38M | 47.94M | - | 0 | -123.46M | -2.58 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioAtla News
Date | Time | Source | News Article |
---|---|---|---|
5/31/2024 | 19:07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
5/17/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
5/14/2024 | 16:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/14/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
3/01/2024 | 15:19 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/21/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
2/20/2024 | 15:22 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/20/2024 | 15:20 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
2/12/2024 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
2/01/2024 | 19:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
1/09/2024 | 08:01 | Edgar (US Regulatory) | Form 8-K - Current report |
1/08/2024 | 16:11 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCAB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.57 | 1.83 | 1.38 | 1.61 | 641,803 | -0.05 | -3.18% |
1 Month | 2.94 | 3.32 | 1.37 | 2.13 | 880,471 | -1.42 | -48.30% |
3 Months | 2.38 | 4.02 | 1.37 | 2.75 | 790,343 | -0.86 | -36.13% |
6 Months | 1.44 | 4.02 | 1.37 | 2.60 | 609,501 | 0.08 | 5.56% |
1 Year | 3.64 | 4.02 | 1.24 | 2.52 | 497,255 | -2.12 | -58.24% |
3 Years | 41.90 | 51.8299 | 1.24 | 7.25 | 546,196 | -40.38 | -96.37% |
5 Years | 30.55 | 76.63 | 1.24 | 9.98 | 504,802 | -29.03 | -95.02% |
BioAtla Description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. |